ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Down 53.2% in January

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 129,600 shares, a drop of 53.2% from the January 15th total of 276,800 shares. Based on an average daily trading volume, of 836,000 shares, the short-interest ratio is currently 0.2 days. Currently, 5.5% of the company’s stock are short sold.

Hedge Funds Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC purchased a new stake in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 1.08% of ZyVersa Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 3.91% of the company’s stock.

ZyVersa Therapeutics Trading Up 4.0 %

Shares of ZyVersa Therapeutics stock opened at $1.31 on Thursday. The firm’s 50-day moving average is $1.24 and its two-hundred day moving average is $1.91. ZyVersa Therapeutics has a 1 year low of $0.98 and a 1 year high of $25.00.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.